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Abstract

Helou, Sami A, M.S. The University of Memphis. April 2011. Evaluating elution &
mechanical characteristics of a calcium sulfate bone graft substitute containing
amphotericin B, cefazolin, or vancomycin. Major Professor: Dr. Joel D. Bumgardner,
Ph.D.

Problem: Osteomyelitis is a major infection that destroys bone. Treatment of the
infection involves use of an injectable calcium sulfate material. This material may be
used for the local delivery of antibiotics at the site of infection to improve clinical
treatment. Studies are needed to determine effects of added antibiotics on injectable
calcium sulfate material properties.
Hypothesis: Antibiotic-loaded injectable calcium sulfate will retain their
chemical/mechanical properties, and elution of the antibiotics will remain large enough to
inhibit any microbial infections.
Aims:
1.

Characterize effects of mixing amphotericin B, cefazolin, or vancomycin on
calcium sulfate’s properties.

2.

Measure elution/dissolution profiles in vitro.

3.

Evaluate eluents ability to inhibit bacterial growth.

Conclusion: There were no adverse effects on the material’s characteristics. Cefazolin
and vancomycin were high enough levels to inhibit in vitro growth of S. aureus.
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Chapter I: Introduction & Specific Aims
Problem Statement
Osteomyelitis is a major concern in orthopedic surgery. A local drug delivery
system involving an injectable calcium sulfate may be an efficient way to eliminate
infections and treat infected orthopedic sites. The advantages of injectable calcium sulfate
for local drug delivery are that it is bioresorbable, osteoconductive, biocompatible, has a
mild set temperature, and may be injected percutaneously. Antibiotics that are considered
by physicians for use in treating osteomyelitis via local delivery with injectable calcium
sulfates include: cefazolin, levofloxacin, linezolid, piperacillin, daptomycin, vancomycin,
and ceftriaxone. However, it is not clear how the addition of these antibiotics may affect
the physical properties important to clinical use of the injectable calcium sulfate materials.
The overall objective of this work is to evaluate the effects of three antibiotics of interest,
amphotericin B, cefazolin, and vancomycin, on physical-chemical properties, and to
determine their release and antimicrobial effects in vitro from a commercial calcium
sulfate injectable graft material, Minimally Invasive Injectable Graft (MIIG)® X3
(Wright Medical Technology, Inc., Arlington, TN). In addition, the majority of the
published data available on the use of antibiotics with calcium sulfate focus on elution of
the antibiotic from a small pellet (~0.1cc), rather than a bolus as would be seen with an
injectable product such as MIIG® X3. Hence, this project will also use an injectable
bolus of size (~5cc) similar to what may be used in clinical applications.
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Aims of this Research
1. Characterize the effects of mixing one of the three antibiotics, amphotericin B,
cefazolin, and vancomycin, on physical, chemical, and mechanical properties of
MIIG® X3. The properties to be evaluated are set time, crystalline phases,
chemistry, and morphology via Vicat and Gilmore penetration tests, X-Ray
Diffraction (XRD), Fourier Transform Infrared Spectroscopy (FTIR), and
Scanning Election Microscope (SEM), respectively. Diametral Tensile Strength
(DTS) will also be performed to provide information on mechanical strength.
2. Measure the in vitro release of the antibiotics from clinically relevant 5cc bolus
samples of injectable material over 28 days in saline solution using High
Performance Liquid Chromatography (HPLC) techniques to determine antibiotic
concentrations in eluent. Also to determine the dissolution of the bolus by change
in mass during the 28 day elution study.
3. Evaluate the ability of the released antibiotics to inhibit the in vitro growth of
representative microbes associated with osteomyelitis via turbidity and zone of
inhibition assays.
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Chapter II: Background
I.

Osteomyelitis
Infection is a major complication in the orthopedic industry. Osteomyelitis is an

infection caused by invading microorganisms that may destroy bone. Osteomyelitis
occurs when a bacteria from a simple wound or cut enters blood and infects bone. It may
also occur from foot ulcers, open fractures, or from surgery that may include an implant.
Osteomyelitis may be characterized as acute or chronic. Acute osteomyelitis refers to a
new infection in bone that develops within two weeks of infection.1 Common symptoms
include swelling, fever, pain, chills, and tenderness. If osteomyelitis persists after 4-6
months even after antibiotic treatment, then it is considered chronic osteomyelitis.
Chronic osteomyelitis occurs in about 2 in 10,000 adults nationwide, but children have it
at a rate of about 1 in 5,000.2 Infected bone may act as a nidus for infection and spread to
other tissues including skin, muscles, or even tendons. Any previous or current injuries or
even surgeries that require an implant like a metal rod/plate to be placed in the bone
increase susceptibility to developing osteomyelitis infection.3 Another problem faced
with osteomyelitis is the possibility of it spreading through the body through the vascular
system.3 Risk factors that may contribute to infection are: diabetes, hemodialysis for
patients with kidney complications, poor blood supply, recent injuries, and even patients
who had a splenectomy.3
A. Infecting Organisms
Bacteria are usually the common microorganisms to cause myelolytic infections,
but fungal infections are possible. Staphylococcus aureus is the cause in 80% of cases
3

reported among 4 year olds to adults.3 Bacteria are split into separate classifications:
Gram positive or Gram negative. Gram-positive bacteria contain a thick layer of
peptidoglycan over the cell membrane, as seen in figure 1. The polymer peptidoglycan is
a combination of sugars and amino acids that creates a mesh-like layer around the
bacteria’s cell membrane. The most common Gram-positive bacteria found in
osteomyelitis are Staphylococcus aureus, Staphylococcus epidermis, Streptococcus
pyogenes, Propionibacterium acnes, and Actinomyces israelii.1,4 Gram-negative bacteria
contain an outer membrane containing lipopolysaccharide and a thin peptidoglycan layer
over the cell membrane, as seen in Figure 1. Lipopolysaccharide is a large polymer
composed of lipid and polysaccharide, which acts as an endotoxin within the body
causing septic shock5. Common Gram-negative bacteria that have been reported to cause
osteomyelitis are: Escherichia coli, Haemophilus influenzae, Serratia marcescens, and
Pseudomonas aeruginosa.1,6 In a clinical study conducted by Meyers, 16 patients
developed osteomyelitis infected by Gram-negative bacteria, which was approximately
28% of all cases osteomyelitis.7
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Figure 1: Schematic of the differences between Gram positive & Gram negative bacteria
modified from Salton et al.8

Fungal osteomyelitis has emerged to become more prevalent within the past few
decades.9 These cases are usually most prevalent in people with depressed immune
systems or diabetic patients with foot ulcers. An estimated 15% or more of diabetic
patients will have a foot fungal infection that may lead to osteomyelitis.4 Fungal
osteomyelitis may occur as a part of a polymicrobial infection or as an isolated condition.
It may spread by from an infected tissue, direct contact with fungi in skin flora or diabetic
ulcers, or via the vascular system as a complication of pulmonary or other type of deep
internal infection.10,11 Common fungi that may cause osteomyelitis are: Candida albicans,
5

Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum, and
Cryptococcus neoformans.12
Some bacteria or fungi may attach to bone or an implanted device and begin to
form a biofilm. Biofilm is the formation of a collection of microorganisms that adhere to
each other and/or to a surface.13 The microorganisms begin to excrete a conglomerate of
extracellular DNA, proteins, and polysaccharides which is called the extracellular matrix.
The extracellular matrix helps promote adhesion, provides protection, and facilitates
communication between the bacterial cells by providing a separate environment from the
rest of the body. It impedes the entry of antimicrobials into the protected environment
and is even strong enough to cause biofilms to become fossilized. 13 Biofilm is difficult to
treat, since the layer of extracellular matrix provides protection to the underlying bacteria.
An estimated 80% of all implant infections have biofilm involvement.14 If the infection is
associated with a metal rod/plate or a prosthetic, biofilm formation may lead for the need
of implant removal.14 If the infection develops into a chronic condition, then surgery,
such as debridement or even amputation, may be needed to prevent spread of infection
through body, especially in diabetics or patients with poor blood supply. 1,15,16
B. Treatment of Osteomyelitis
Several treatments for osteomyelitis infection include systemic antibiotics,
surgical debridement with/without antibiotics, local drug delivery systems, and
amputation or removal of implant.4 One or more treatment methods may be combined to
combat osteomyelitic infection. Systemic antibiotics may be administered for up to a
month, with some treatments lasting up to 42 days.16 Systemic antibiotic treatment may
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be successful for acute osteomyelitis, but this treatment approach will not usually work
with patients with chronic osteomyelitis or diabetic patient due to local damage to the
vascular system.16 Surgical debridement is the next course of action and requires removal
of a patient's dead, damaged, or infected tissue. This approach helps prevent the
remaining healthy tissue from becoming infected and also allows bone and soft tissue to
begin new tissue formation.17 Even if osteomyelitis is treated with systemic antibiotics,
surgery may be required to remove dead tissue or an abscess left behind after treatment.
Debridement removes the infection, but it is painful for the patient and incisions may
generate new infections.17 If a resulting void is produced after surgery, it may be packed
with a bone graft, such as calcium sulfate or calcium phosphate, that promotes the growth
of new bone tissue or bone filler. Bone graft and bone filler materials have been used
successfully for locally delivering antibiotics to treat osteomyelitis.17-27 If all treatments
fail, amputation or implant removal becomes the patient’s last resort.
II.

Local Drug Delivery
Challenges in systemic treatments of osteomyelitis or in preventing re-infection in
bone are delivering the antibiotic to the site at an effective concentration and for duration
to abate the infecting agents. Complications arise due to the relatively poor or
compromised blood supply and the nature of the biofilm itself.16 Local drug delivery
systems may help prevent or combat infection by overcoming limits of systemic delivery,
such as adverse immune response from a high antibiotic concentration.16 The advantages
of local delivery are that this treatment mostly allows antibiotics to be delivered directly
to the site of infection more efficiently and at higher doses than systemic delivery.16 This
advantage helps eliminate vascular issues for diabetic patients or in areas of low blood
7

circulation, such as cartilage or bone.16 Drug compliance issues that physicians encounter
with patients are eliminated.16 Drug compliance issues include whether a patient is taking
the medication, whether they are taking the correct amount, and whether they complete
the course of the medication to insure infection is gone.
Local drug delivery methods used to treat osteomyelitis are antibiotic-loaded
PMMA, calcium sulfate, calcium phosphate, and synthetic and natural polymers. The
ideal local drug delivery system for osteomyelitis would be one that is able to release a
high concentration of antibiotic to abate infection and subsequently a gradual declining
concentration to avoid inducing antibiotic resistance, be osteoconductive, biocompatible,
and bioresorbable, and be able to have some functional strength.17-27 The material may
encounter mechanical stresses from the patient moving, especially if the material is being
used to hold an implant in place.31,47 Calcium sulfate and calcium phosphate are
resorbable and biocompatible material, therefore the dissolving ions may combine within
body fluids and not elicit an immune response.29 In most cases, osteoconductivity is
promoted while the biomaterial is resorbing. The optimal antibiotic release profile is an
initial burst release to combat the onset of infection directly after surgery and then a
slower release during 4-6 weeks while the patient is healing to ensure re-infection does
not occur.16
A. PMMA
The addition of antibiotics to PMMA was one of the earliest types of local drug
delivery systems. The advantage of PMMA is that it has a very slow and prolonged
antibiotic release into the body. The disadvantage of PMMA is that it is not resorbable
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and must be removed from the body.29,30 If it is not removed, there is always the
possibility of a biofilm forming on the surface of the material, which may cause the
infection to be harder to treat. Antibiotic-loaded PMMA is usually made by adding
antibiotic to the mixture of PMMA powder and monomer solution and then spreading
material over a polymer mold plate to form beads. PMMA beads are packed into bone
voids, especially ones created after debridement. PMMA may also be used as bone
cement in revision orthopedic surgery, such as the Prostalac® hip offered by DePuy
(Warsaw, IN).31 Studies have been shown that antibiotics are only eluted from the outer
surface area and the remaining antibiotic may be sequestered inside the bead for up to 10
years due to the PMMA’s less porous surface characteristics.32 PMMA beads typically
require removal due to their limited elution profile and their presence as a foreign body.
Even with these disadvantages, PMMA is still the most common form of local drug
delivery.33
B. Collagen, Chitosan, Synthetic Polymers, & DBM
Collagen and chitosan have both been used to deliver antibiotics, but they often
require chemical modification to control degradation rates.30,34,35 Their biocompatible and
bioresorbable characteristics make them appealing for local drug delivery, but both are
usually used as hemostats to control bleeding and cannot endure mechanical stresses that
bone cements do.36 Synthetic polymers, such as polyglycolic acid and polylactic acid, are
usually not as popular in local drug delivery, because of their characteristics to elicit an
inflammatory response when they begin to degrade due to acidic degradation products.37
Demineralized bone matrix (DBM) is also another possible bone graft material suitable
for local drug delivery. The material is osteoinductive, osteoconductive and bioresorbable.
9

Wright Medical offers a product called Allomatrix® Injectable Putty that contains 86%
by volume of DBM, while the rest is cancellous bone chips. In a study conducted by
Lewis et. al, Gentamicin was loaded into DBM and the amount of antibiotic released or
eluted in saline solution was measured.38 They reported that the levels of antibiotic
released were high enough to inhibit S. aureus for at least 13 days in vitro. They also
determined that the antibiotic had no adverse effects in vitro on the osteoinductive nature
of the DBM. A disadvantage of DBM is that it is dead bone and may act as another site
for the osteomyelitic infection to spread when placed into a previously infected site.
C. Calcium Phosphate/Hydroxyapatite
There have been many studies and reviews of calcium phosphate materials being
used as local drug delivery systems.18-21,39,40 Advantages of calcium phosphate are its
biocompatible and resorbable characteristics when implanted in the body. Calcium
phosphate may be made injectable by combining with sterile water, which is a great
characteristic for use in minimally invasive surgery and in the treatment of difficult
accessible sites. In the study conducted by Shinto et al, each porous hydroxyapatite block
was successfully made by mixing the powder with 75mg of one of the following
antibiotics: gentamicin, cefoperazone, or fiomoxef. 18 The antibiotic concentrations
released were effective in inhibiting S. aureus in vitro for as long as 12 weeks. Calcium
phosphate may be made to have a highly microporous structure that allows incorporation
of many types of drugs and biologically active molecules such as growth factors, antiinflammatory and anti-cancer drugs, without losing activity and denaturalization. 18,20,21
Calcium phosphate is not always porous and does have its disadvantages. It does not have
the ability to release high concentrations of antibiotic and normally has a long dissolution
10

time, unless modified to resorb quicker. The long dissolution time with no or reduced
antibiotic release may allow biofilm formation on the surface of the material and promote
microbial proliferation.20,24
D. Calcium Sulfate in Local Drug Delivery
Calcium sulfate has been used as bone void filler for over 100 years. Calcium
sulfate was first used for antibiotic delivery in the 1950’s, with studies showing that it
may resorb and promote bone growth.41,42 It has become increasingly popular for drug
delivery and has seen a higher rate of use with many antibiotics as compared to calcium
phosphate, PMMA, collagen, and chitosan.20 Biocompatible, biodegradable,
osteoconductive properties, and similar mechanical strengths as bone are all reasons
calcium sulfate is used. For local drug delivery, calcium sulfate is selected for
injectability and low setting temperature that allow incorporation of drugs without the
potential of denaturing as may occur with PMMA. 20
a. History of Calcium Sulfate
Calcium sulfate is a very common compound and often found in laboratory or
industrial environments. Calcium sulfate is not only used in the medical industry, but also
in the baking industry, brewing industry, and pharmaceutical applications, such as dietary
calcium supplements.43 The material may also be used as a desiccant in its anhydrous
state, called γ-anhydrite, or as a moisture indicator, called Drierite. 44 Naturally, calcium
sulfate is a translucent, crystalline white rock and may be found at many locations
worldwide, especially in Paris where it derives one its names, plaster of Paris. Calcium
sulfate is a by-product of many processes: flue gas desulfurization, production of
11

phosphoric acid from phosphate rock, production of hydrogen fluoride, and refining of
zinc.44 World production of natural gypsum, calcium sulfate’s most stable form, is around
127 million tons per annum.45 It was believed to have been discovered as far back as 975
A.D. by a Persian pharmacist.46
Calcium sulfate hemihydrate (CaSO4·½H2O) will convert to calcium sulfate
dihydrate (CaSO4·2H2O) when mixed with water by the following weak to moderate
exothermic chemical reaction: CaSO4·½H2O + 1½ H2O → CaSO4·2H2O.44,47 The
exothermic reaction allows the larger crystals to interlock and harden, creating a melting
point of 1450 °C.45 The hemihydrate (plaster of Paris) will become a dihydrate
(gypsum/terra alba), which is a hard, cement-like material. Hemihydrate comes in 2
forms: α-hemihydrate, found in medical applications and β-hemihydrate, found in
commercial applications.48 β–hemihydrate requires more water for hydration and
therefore will former a stronger structure, but not in medical uses.48 Gypsum has a
naturally occurring anhydrous form called β-anhydrite and may be heated to de-hydrate it
back to hemihydrate; the process is also called calcination.
b. Previous Studies with Antibiotic-loaded Calcium Sulfate
Many research and clinical studies evaluating calcium sulfate for local delivery of
antibiotics such as gentamicin, amikacin, tobramycin, and daptomycin to treat
osteomyelitis are available.22-27,30,48,49 Miclau et al. compared the release of tobramycin
from calcium phosphate, calcium sulfate, DBM, and PMMA using 6x4 mm pellets.49
Calcium phosphate and DBM eluted 70% and 45% respectively of their antibiotics by 24
hours and negligible amounts were measured at week 1. Calcium sulfate and PMMA had
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elution rates of 17% and 7% respectively at 24 hours and trace amounts at 2 to 3 weeks.
They concluded that calcium phosphate and DBM were good carriers for brief antibiotic
coverage, such as for open fractures, while calcium sulfate and PMMA were better for
long term coverage, such as osteomyelitis.
Nelson et al. used New Zealand white rabbits infected with S. aureus and
demonstrated that tobramycin-loaded calcium sulfate pellets abated 85% of infection than
rabbits treated with debridement only (42%), placebo pellets and intramuscular injected
tobramycin (36%), or placebo pellets (23%).50 This study concluded that calcium sulfate
has potential utility as a biodegradable local antibiotic delivery system in the treatment of
musculoskeletal infections.
Wright Medical Technology offers a pre-formed calcium sulfate pellet product,
OSTEOSET® T that incorporates the antibiotic tobramycin sulfate into the material. 47
This product is not approved for market in the United States.47 Tobramycin sulfate is in
the aminoglycoside family of antibiotics, and is very useful in treating Gram-negative
bacterial infections and S. aureus and S. epidermis.47 The success of local delivery
through the use of calcium sulfate in products such as OSTEOSET® T has helped stir
interest in other calcium sulfate products with different types of antibiotics, but effects of
mixing antibiotics with calcium sulfate on properties of the calcium sulfate are not
always well documented.
Webb et. al reported that setting characteristics of calcium sulfate may be affected
by the addition of an antibiotic.30 In their study, daptomycin (CUBICIN®), a new
lipopeptide antibiotic used for treating resistant Gram-positive bacteria, prevented
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calcium sulfate from setting unless an accelerant, potassium sulfate was added. The
chemical composition of daptomycin inhibited the conversion of hemihydrate to
dihydrate, until potassium sulfate was added. Once potassium sulfate was added, the
antibiotic was eluted as expected, with a large initial release on day 1 and gradual
decrease over the next 28 days. The daptomycin-loaded pellets also dissolved more
quickly than tobramycin-loaded pellets. They also determined that the eluents from the
drug loaded pellets were still able to inhibit S. aureus and S. epidermis growth in vitro.
A study by Doadrio et al. conducted XRD and FTIR tests on their cephalexinloaded calcium sulfate pellets and concluded that the presence of the drug had no effect
on the physical-chemical behavior of the bone grafts nor affected structural changes to
the pellets.25 While they noted no effect of drug on some properties of the calcium sulfate,
they did not determine release or bioactivity of the drug. Cephalexin is a cephalosporin
antibiotic that is in the same class of antibiotic as cefazolin with very similar structures
and mechanisms of action.
There are studies conducted on cefazolin and vancomycin-loaded calcium sulfate
in the pellet form.22-27 A study by Jackson et. al demonstrated that vancomycin loaded
into rapidly resorbing calcium sulfate pellets did have a higher antibiotic release profile
when compared to amikacin and gentamicin.48 In this study, they developed a pellet that
may fully dissolve within 24 hours. Amikacin and gentamicin pellets fully dissolved and
eluted antibiotic within 12 hours, while vancomycin pellets released antibiotic out to 24
hours. Vancomycin had a spike in release at 1 hour and then another burst at 4 and 8
hours and then slowly decreased until it dissolved. They contributed the slower release to
vancomycin’s larger nine ring structure.
14

Heijink et al. conducted an in vitro study where they were able to retrieve 39% of
their vancomycin from OSTEOSET®, a calcium sulfate product also offered by Wright
Medical.24 In the study, they also mixed vancomycin with DBX®, an allograft bone void
filler made by Synthes® (West Chester, PA), and Collagraft®, a synthetic bone graft
comprised of bovine collagen and hydroxyapatite/tricalcium phosphate (HA/TCP)
granules that is made by Zimmer® (Warsaw, IN). They were only able to retrieve 9% and
23%, respectively, of the vancomycin, which further supports that calcium sulfate may be
more suitable for local drug delivery applications.
In a study conducted by Xie et. al, vancomycin-loaded calcium sulfate pellets
were compared to vancomycin-loaded borate glass.26 Borate glass was made by replacing
the SiO2 in silicate-based bioactive glass with B2O3, Over 65 rabbits were infected by
percutaneously injecting methicillin-resistant S. aureus (MRSA) into the medullary
cavity through the lateral aspect of the proximal tibial metaphysic. Each rabbit received
treatment by debridement and the void was filled with: nothing (group 1), pure borate
glass (group 2), vancomycin-loaded calcium sulfate (group 3), and vancomycin-loaded
borate glass (group 4). The vancomycin-loaded calcium sulfate and borate glass had the
best inhibition rates against the MRSA with 73.33% and 81.25%, respectively. It was
observed that the calcium sulfate had fully resorbed and had better bone growth
compared to the borate glass only being partially reabsorbed.
Another study done by Udomkusonsri et al. showed that cefazolin-loaded calcium
sulfate beads had a recovery rate of 93.84% after a 15 day elution study in PBS. 27 They
only had a 24.10% recovery rate for cefazolin-loaded PMMA beads. They believed
calcium sulfate had a higher porosity which contributed to the higher antibiotic release.
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Their results demonstrated that calcium sulfate may release antibiotic at a much higher
concentration and be better in local drug delivery compared to PMMA. They also tested
in vitro the cefazolin eluents effectiveness against Bacillus subtilis, a Gram-positive
bacteria. Eluents inhibited the bacteria’s growth successfully and they determined that
mixing cefazolin with calcium sulfate would not affect cefazolin’s antibacterial activity.
A study conducted by Edin et al. tested the effects of cefazolin and vancomycin
on osteoblast-like cells.23 They used MG-63 human osteosarcoma cell line and exposed it
to different concentrations of the antibiotics ranging between 0 to 10,000µg/mL and then
100 to 1000µg/mL to define cefazolin’s toxic level. They determined that levels of
1000µg/mL or less for vancomycin and 100µg/mL or less for cefazolin have little or no
effect on the cells. But concentrations of 10,000µg/mL for vancomycin and cefazolin
caused cell death. Levels of 200µg/mL for cefazolin did cause significant decrease in cell
replication. They concluded that vancomycin is less toxic than cefazolin at higher
concentrations and may be a better antibiotic for local drug delivery.
III.

The Use of an Injectable Calcium Sulfate for Local Antibiotic Delivery
Injectable bone grafts/cements were developed for percutaneous injection of
calcium phosphate, PMMA, and calcium sulfate in minimally invasive surgery and in the
treatment of sites that are difficult to access.47 Smaller incisions help keep the risks of
infection low. Lieberman et al. wrote a review paper discussing the characteristics of
injectable bone cement during percutaneous vertebroplasty, which is the percutaneous
injection of PMMA into a collapsed vertebral body.51 Kyphoplasty may also be done and
is an advanced minimally invasive technique. Both procedures are done to help stabilize
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the vertebrae. New bone cements, such as calcium sulfate or calcium phosphate, are
being incorporated into surgeries for their good biocompatibility, biomechanical strength
and stiffness, and radiopacity for the fluoroscopy guided procedures. 51
Hesaraki et al. conducted a study where injectable macroporous calcium
phosphate was mixed with cephalexin.52 They used sodium dodecyl sulfate to increase
porosity in calcium phosphate to help increase injectability and for rapid bone resorption.
They concluded that addition of the cephalexin caused the material to set slower,
decreased crystallinity of formed apatite phase, but it did improve injectability. In a study
conducted by Urban et al., calcium phosphate and calcium sulfate were mixed with sterile
water to develop an injectable composite bone graft. 40 The ultimate compressive strength
and elastic modulus of the composite graft were compared to calcium sulfate pellets and
normal canine bone. In vivo tests with canine models resulted in a small amount of the
composite graft remaining after 26 weeks, while none remained for calcium sulfate
pellets. Ultimate compressive strength and elastic modulus were higher for the composite
graft compared to calcium sulfate pellets. They determined that the calcium
sulfate/calcium phosphate composite would be successful in clinical applications that
required a strong, injectable, slower-resorbing, and biocompatible bone graft substitute.
Wright Medical Technology (WMT, Arlington, TN) began marketing an
injectable calcium sulfate bone substitute, Minimally Invasive Injectable Graft (MIIG)®
X3 in May 2003. MIIG® X3 is an injectable calcium sulfate bone graft substitute that is
used in filling non-load bearing bone voids and fractures.47 The MIIG® X3 kit comes
with a specially designed vacuum mixing bowl, syringe, and injection needle, shown in
Figure 2. The kit also comes with a premeasured amount of sterile Water for Irrigation,
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USP (WFI). Under vacuum pressure, the kit is mixed at a rate of approximately 2
revolutions/second. The product is percutaneously injected while in the hydrated state,
and typically sets within 7-10 minutes to provide a strong, rigid structure for implant
fixture or filling up a bone void.47 The material’s ability to be injected into a bone void
and its quick set time gives it useful characteristics for use in local drug delivery during a
minimally invasive surgery. When calcium sulfate is injected, it will not have the same
structure as a pre-made pellet. It will appear more as a bolus; small surface area covering
a larger volume of calcium sulfate. The evaluation of drug release from a bolus sample is
a focus of this investigation. While many studies of solid/preformed calcium sulfate
pellets with antibiotics may be found in literature, few studies can be found on adding
antibiotics to commercially available injectable calcium sulfate bone graft.

B

A

Figure 2: A. MIIG® X3 Kit offered by Wright Medical Technology, Inc.
(Arlington, TN) and B. X-Ray illustrating bolus injected into bone47
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IV.

Antibiotics
Many antibiotics have been investigated for local delivery using calcium sulfate
materials. 22-27,30,48,49 This investigation will be focused on three antibiotics, amphotericin
B, cefazolin, and vancomycin. These selected antibiotics represent a variety of antibiotic
classes and will be evaluated in this preliminary investigation. Selection of these
antibiotics was also based on ability to manipulate the concentrations as needed for
mixing directly with commercial injectable calcium sulfate cement. Drug availability,
prices of the drug, and ability to measure eluents were also considered before choosing. A
brief background of each of these antibiotics follows.
A. Amphotericin B
a. Description
Amphotericin B is a polyene antifungal that was extracted from Streptomyces
nodosus, a filamentous bacterium originally found in Venezuela. Some trade names that
Amphotericin B goes by are: Fungilin, Fungizone, Abelcet, AmBisome, Fungisome,
Amphocil, and Amphotec.53 It derives its name from its amphoteric characteristics,
meaning it has acidic and basic chemical properties.
b. Mode of Action
The mechanism of action for this antifungal is by targeting ergosterol, the main
component of fungal cell membranes. The antifungal agents forms a transmembrane
channel that leads to monovalent ion (K+, Na+, H+, Cl-) leakage which leads to fungal
death.54
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c. Where & Why Used
This antifungal agent is typically given intravenously to patients with systemic
fungal infections, but this agent has also been known to work against protozoan
infections. Amphotericin B is available as a cholesteryl sulfate complex, lipid complex,
and as a liposomal formulation, but the form used in this study was cholesteryl sulfate
complex.53,55
d. Dosage
Under no circumstances should a total daily dose of 1.5 mg/kg be exceeded. 54
Optimal dosage for amphotericin B is unknown due to its toxicity, but for Candidiasis it
is approximately 0.5-1mg/kg/day, which must be infused over 2-6 hours and vital signs
of patient must be checked on every 15 minutes during infusion. A test dose of 1mg must
also be given over 1 hour before any more may be administered.
e. Adverse/Side Effects
The problem with Amphotericin B’s mechanism of action is that it also targets
sterols in human cell membranes, which leads to toxicity for human cells.54 Additional
side effects of amphotericin B include fevers, chills, headaches, irregular heartbeat,
nausea and vomiting. Adverse effects are much worse and may lead to multiple organ
damage if it is not administered properly. 53
f. Pertinence to Local Delivery
The purchased powder form was insoluble in water, but was soluble in a solution
of methanol, dimethyl sulfoxide, and dimethylformamide. This study will also investigate
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whether this poor solubility would detract from this antifungal agent being used clinically
with an injectable calcium sulfate bone graft for local antibiotic delivery. Overall,
amphotericin B was selected for its proper antifungal characteristics.
B. Cefazolin
a. Description
Cefazolin is a cephalosporin antibiotic, which is a class of β-lactam antibiotics. βlactam antibiotics contain a nucleus composed of a lactam with a heteroatomic ring
structure, consisting of 2 carbon and 1 nitrogen atoms. 56 Cefazolin is often sold under the
names: Ancef, Cefacidal, Faxilen, Novaporin, Reflin, Zinol, and Kefol.
b. Mode of Action
The antibacterial works by disrupting the synthesis of the peptidoglycan layer of
bacterial cell walls.57 β-lactam antibiotics bind to a site where penicillin-binding proteins
(PBPs) are required to facilitate synthesis of peptidoglycan. Antibacterial agents mimics
PBPs and binds to the site to prevent cross linking, causing the peptidoglycan layer to
eventually fail.58
c. Where & Why Used
The drug is administered by either intramuscular or intravenous injection.
Cefazolin is effective against mostly Gram-positive bacteria such as staphylococci and
streptococci bacteria, and is also effective against the Gram-negative bacteria Escherichia
coli. The antibacterial is mostly used to treat skin infections, but may also be used to treat
moderately severe bacterial infections.
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d. Dosage
Dosage is based on moderate to severe infections is usually around 500mg-1g
every 6 to 8 hours orally and may go above 1g doses if infection is life-threatening.57
e. Adverse/Side Effects
Adverse effects for cefazolin are very rare, but possible side effects are usually
stomach aches, diarrhea, or vomiting.58
f. Pertinence to Local Delivery
Cefazolin was selected, because it is a β-lactam antibiotic and its mechanism of
action help fight off E. coli and S. aureus, who are major players in osteomyelitis.
C. Vancomycin
a. Description
Vancomycin (sold as Vancocin, (manufacturer), or COVANC, (manufacturer) is a
glycopeptide antibiotic, which is a class composed of glycosylated cyclic or polycyclic
nonribosomal peptides. The antibacterial was isolated from the bacteria Amycolatopsis
orientalis from the jungles of Borneo.59
b. Mode of Action
Like cefazolin, vancomycin inhibits the synthesis of the bacterial peptidoglycan
layer; however, the mechanism for this inhibition is different. 60 The antibiotic prevents Nacetylmuramic acid (NAM) and N-acetylglucosamine (NAG) subunits from combining
with peptidoglycan, which eventually leads to its failure.61
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c. Where & why used
Vancomycin is effective against Gram-positive bacteria, especially S. aureus, but
is not effective against Gram-negative bacteria. The antibacterial is administered orally
for colon infections and intravenous injections for systemic infection. Vancomycin is
only used in the line of last defense in serious, life-threatening infections, due to its high
potential for toxicity in the body and for increased antibiotic resistance which has
developed to more common antibiotics. 61 Vancomycin is usually effective against
bacteria resistant to penicillins, such as methicillin-resistant S. aureus (MRSA), and is
also useful for patients with allergies to penicillins.
d. Dosage
Intravenous dosages are 2 g divided either as 500 mg every 6 hours or 1 g every
12 hours. Each dose should be administered at no more than 10 mg/min. 60
e. Adverse/Side Effects
Side effects may range from hearing loss, fever, chills, fainting, skin rash,
diarrhea, and nausea. Adverse effects include nephrotoxicity and ototoxicity; therefore,
the drug must be administered carefully.59
f. Pertinence to Local Delivery
There has been an increased amount of vancomycin-resistant bacteria, which has
caused serious concern in health officials.62 Vancomycin was chosen for its effectiveness
against MRSA bacteria and its mechanism of action.

23

Chapter III: Hypothesis
The overall objective of this study is to evaluate the potential from injectable
calcium sulfate bone graft to be used as a local drug delivery system for the antibiotics
amphotericin B, cefazolin, and vancomycin. In this study, mechanical and physicalchemical properties of the antibiotic-loaded calcium sulfate bolus will be evaluated and
antibiotic release and activity against model bacteria determined. The specific hypot of
this study is that calcium sulfate bone graft retains its physical-chemical and mechanical
properties when mixed with antibiotics. For up to 28 days, elution of the antibiotics will
remain above the minimum inhibition concentration (MIC) and will inhibit any microbial
infections. The larger bolus will not dissolve completely and will release antibiotic till the
end of the study.
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Chapter IV: Materials & Methods
In this investigation, the commercially available injectable calcium sulfate bone
graft, Minimally Invasive Injectable Graft (MIIG)® X3, from Wright Medical
Technology (Arlington, TN) was evaluated as a local antibiotic drug delivery mechanism.
This material was selected because of availability and current use clinically, its ability to
be injected percutaneously in its hydrated state and would typically set within 7-10
minutes. The antibiotics, cefazolin, vancomycin, and amphotericin B, were selected for
evaluation for delivery from the MIIG® X3 product because of their antimicrobial effect
on common pathogens that may cause osteomyelitis. The effects of adding the antibiotics
on the physical properties of the MIIG® X3 product will be evaluated since effects are
not well documented. The parameters investigated included set-time via Vicat/Gilmore
penetration tests, Calcium Sulfate conversion via X-Ray Diffraction (XRD), chemical
structure via Fourier Transform infrared Spectroscopy (FTIR), surface characteristics via
Scanning Electron Microscopy (SEM), and mechanical properties via Diametral Tensile
Strength (DTS) testing. The release and activity of the eluted antibiotics over 28 days,
which is commonly used, was also evaluated via High Performance Liquid
Chromatography (HPLC) and bacterial growth inhibition in turbidity assays respectively.
In the experiment, replicate samples (n=5) of MIIG® X3 for each antibiotic were made
from individual kits. Replicate samples (n=5) of MIIG® X3 made from individual kits
without any antibiotic were used as controls.
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I.

Mixing MIIG® X3 with Antibiotic
An antibiotic dosage of 1g of cefazolin, 1g of vancomycin, or 50mg of
amphotericin B was added to 35g of calcium sulfate in the 15cc MIIG® X3 kit resulting
in mixtures containing ~2.9 weight% of cefazolin or vancomycin, or ~0.14 weight% of
amphotericin B based on calcium sulfate powder. The chosen dosage was based on
clinically relevant amounts that may be safely administered to patients.54 The dose of
amphotericin B was used at lower concentration than vancomycin and cefazolin to avoid
potent cytotoxic effects.68
The antibiotics came in a powder form and were reconstituted in 4mL of water for
Irrigation, USP (WFI). After the antibiotic had dissolved in the WFI, the calcium sulfate
powder was added and mixed at a rate of 70 revolutions in 30 seconds in the supplied
mixer from the kit (84XS-0405: mini MIIG® X3 High Strength Injectable Graft and
84XS-0415: MIIG® X3 High Strength Injectable Graft). Cefazolin and vancomycin fully
dissolved in the WFI and were used immediately to prepare the calcium sulfate cement.
Because of the previously discussed poor solubility of the amphotericin B, mixing in WFI
was extended to 3 minutes prior to mixing with calcium sulfate powder. Methanol or
dimethyl sulfoxide was not used as solvents, since it would have not been clinically
relevant. Immediately after mixing each batch, a sample was taken for evaluation of set
time. Each batch was further divided in to samples for XRD, SEM and FTIR testing.

II.

Set Time Testing
The Vicat test, developed per ASTM Standard C472.26 (Standard Test Methods
for Physical Testing of Gypsum, Gypsum Plasters and Gypsum Concrete, ASTM, Inc.,
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PA, USA), is used to determine the set time (minutes) of the bone graft. The test is based
on the penetration of a 1 mm diameter flat head needle into the cement under a constant
load (300g); set time is established as the time it takes for the needle to penetrate less
than half the original distance. Immediately after mixing with or without antibiotic
solution, approximately 15mL of cement was poured into a 60mm diameter by 15mm tall
container and then a Buffalo Vibrator (Model # 200) was used to remove air bubbles and
create a flat surface. Samples were tested using the same bolus volume of 15mL of mixed
cement and penetration measurements were performed at 30 second time intervals until
the material set. Testing began to lose its surface gloss and was repeated at 30 second
time intervals until the material set as described through needle penetration. The needle
was cleaned and a new test location used each time. If the needle fell less than half the
original distance it was considered set. Each antibiotic mixture were tested along with a
control (no antibiotic) with a replicate (n=5) for each configuration.
The Gilmore test, developed per ASTM Standard C266.89 (Standard Test Method
for Time of Setting of Hydraulic-Cement Paste by Gilmore Needles vol 04.01, ASTM,
Inc., PA, USA), was also used to determine the set time of the mixtures. The method is
very similar to the Vicat test, except for two differences. The first difference was the
Gilmore apparatus contained 2 stainless steel needles with 4.8mm cylindrical flat-ends:
Gilmore 1 contains 1.06mm diameter and 113.4g weight for initial set; Gilmore 2
contains a 2.12mm diameter and 453.6g weight for final set. The second difference is the
Gilmore set time was recorded when the needle leaves no appreciable indentation on the
sample surface.
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III.

Calcium Sulfate Conversion
X-Ray Diffraction (XRD) was used to evaluate if any un-reacted or nonconverted material remained after mixing MIIG® X3 with the antibiotic. After mixing for
initial penetration tests, material was allowed to finish setting for at least 24 hours before
performing XRD, FTIR, and SEM. Set samples for XRD analysis were crushed using a
mortar and pestle to make a powder. XRD spectra were obtained using a Bruker D8
Advance X-Ray Diffractometer. The scan range for 2Θ was set to approximately 10 to 60°
to ensure all peaks were captured. Peaks at 2Θ = 29.1° and 2Θ = 29.7° were associated
with dihydrate and hemihydrate, respectively. Percentage of hemihydrate and dihydrate
were calculated by the following equation:

% Hemihydrate or Dihydrate = (intensity of hemihydrate or dihydrate/intensity total
of both hemihydrate and dihydrate) * 100

IV.

Chemical Structure
Fourier Transform Infrared Spectroscopy (FTIR) analysis was used to determine
the overall composition of the set test mixtures with antibiotics and compared to the
controls that did not contain any antibiotics. When infrared radiation is passed through a
sample, light is absorbed while the rest is transmitted. A spectrum is produced that
represents the molecular absorption and transmission, which creates a molecular
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fingerprint of the sample. A background reference was collected before each sample run.
Set samples for FTIR analysis were crushed into a powder using mortar and pestle. The
powder was placed on a plate that contained a diamond/ZnSe crystal in the center on the
Standard Sample Holder and compressed. Spectra were collected using a Nicolet iS10
FTIR Machine (Vernon Hills, IL).
V.

Surface Characteristics
Surface morphology of the set test and control cement samples was observed
using a Scanning Election Microscope, SEM (LEO 1450 Variable Pressure Scanning
Electron Microscope, Clifton Road, England). Images were taken for each type of
calcium sulfate/antibiotic mixture, including controls for comparison, at various
magnifications: 1000x, 1500x, and 2500x. Images were analyzed for any differences
between surface features, such as crystalline form, pores, and crater formation. Also,
Energy-Dispersive X-Ray Spectroscopy (EDS) was conducted to measure the amount of
certain elements (carbon, oxygen, calcium, and sulfur) in each sample for the purpose of
comparing to the control.

VI.

Mechanical Testing
Diametral Tensile Strength (DTS) test was used to determine whether the
mechanical strength of MIIG® X3 changed due to the addition of the antibiotics. After
mixing, MIIG® X3 was injected into a 15mm symmetrical polyurethane foam cube with
a 10 mm open cylindrical void and allowed to harden under wet or dry conditions. For
wet conditions, samples were allowed to cure in bovine calf serum at 37°C. For dry
conditions, specimens were cured in air at room temperature. Samples in the wet or dry
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cure condition were tested at 1 hour or 24 hours post-mixing. Immediately prior to testing,
the side faces of the cube were removed with a razor blade following pre-cut tabs, so that
the cylinder was longitudinal between the top and bottom faces. The faces above and
below the sample were compressed until failure, which appeared as a vertical crack as
seen in figure 3. Tests were performed using an Instron Model 33R 4465 with a 5kN load
cell. Samples were compressed at 1.5mm/min. Tests were stopped if the load reached
above 1.6kN and dropped more than 1%. Amount of force (N) at failure was collected
and used to calculate DTS in the equation:

DTS = 2*Pmax/ (π*H*L),

where Pmax = force at failure (N), H = 10mm, and L = 15mm. Five samples of each test
antibiotic mix and control (no antibiotic mixed) MIIG® X3 in each condition (wet/dry,
1hr/24hr cure) were evaluated.
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Figure 3: A. Before & B. After of Sample Being Compressed in DTS testing

VII.

Elution Testing:
To simulate volumes used clinically and to ensure similar size and shape of bone
graft specimens for elution testing, MIIG® X3 – 5cc was mixed with appropriate amount
of antibiotics to keep same weight% as previously described and then injected into a
silicone elastomer mold, 0.75 inch inner radius and 1 inch tall, and the top surface
flattened with a spatula. The bolus appears as a much larger pellet, but the bolus was
injected into the mold compared to a pellet being made by pouring the material over a
silicone-molded plate and then removing excess with spatula. 30,47,48 After allowing the
samples to set for at least 10 minutes, they were removed from the mold and allowed to
complete setting overnight under sterile vent hood. Each bolus was weighed to record
mass before elution testing and then placed in 50 ml test tubes (one bolus per tube) with
20 ml sterile phosphate buffered saline (PBS), which completely covered the bolus. The
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tubes with test and control boluses were placed in 37°C incubator to replicate body
temperatures. The solution was changed on days 1, 2, 3, 5, 7, 14, 21, and 28; eluent
samples from each time point were stored at -80°C. At the end of testing, remaining
boluses were retrieved, allowed to dry overnight, and re-weighed to determine the
amount of mass loss.
The amount of antibiotics released from the bolus was measured via HPLC
(Varian ProStar 325 system with UV-Vis Detector modules and Galaxie Chromatography
software (v1.8.508.1)). Eluents were tested within 7 ± 1 days of being stored in the -80°C
freezer and each antibiotic was tested separately. Table 1 contains information on the
HLPC mobile and stationary phases, flow rates and detection wavelengths used for
detecting the test antimicrobials. A calibration curve was obtained using known serial
dilutions of the antibiotic in PBS; range was from ~10µg/mL - 2000µg/mL. The amount
of antibiotic concentration (µg/mL) in the collected eluents was determined using the
standard curve.
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Table 1: Chemical solvents and columns to be used for analyzing antibiotics via HPLC
methods
Antibiotic being
measured
Amphotericin
B63

Mobile Phase
Acetonitrile-acetic
acid-water mixture
(52:4.3:43.7 v/v/v)

Stationary Retention Flow Wavelength
Phase
Time
Rates
Peak
C18
12.5 min
1
407nm
column
mL/min

Cefazolin64

0.02 M Sodium
phosphate
monobasic (pH 5)
and methanol (80:20
v/v)

C18
column

14 min

1
mL/min

270nm

Vancomycin65

Acetonitrile and
H2O (38:62 v/v)
combined with
40mM NH2PO4 (pH
4 adjusted w/glacial
acetic acid)

C18
column

4.5 min

0.5
mL/min

243nm

It is noted that the HPLC method, including different mobile phases, used to
determine concentrations of amphotericin B in test eluents was unsuccessful because of
the insolubility of the drug in aqueous solutions.
VIII.

Turbidity Study
A turbidity study was conducted using the eluents from the cefazolin and
vancomycin containing calcium sulfate cement samples to determine activity of the
released drugs to inhibit bacterial growth. The Cowan I strain of S. aureus was used for
the turbidity tests and was grown overnight at 37°C in trypticase soy broth (TSB) and
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was further diluted 1:5 in TSB before using it for inoculation. The turbidity testing
scheme is outlined in Table 2. Each test for cefazolin and vancomycin had 3 positive
controls (bacteria inoculum only), 3 negative controls (no bacteria or test eluents), and 7
blank tubes that were used to ensure that the test eluent (PBS) did not contain anything
that may interact with TSB and alter its absorbance. Eluents collected at each time point
(7 time points) from test and control calcium sulfate samples (n=5) were evaluated.

Table 2: Volume amounts of each liquid added to specific test tubes
Tube
Positive
Control
Negative
Control
Blank Tubes
Test Eluent
Control Eluent

Volume of
TSB
1.75mL

Volume of
PBS
200µL

Volume of
Eluent
X

Volume of
Bacteria
50µL

1.80mL

200µL

X

X

1.80mL
1.75mL
1.75mL

X
X
X

200µL
200µL
200µL

X
50µL
50µL

Since the minimum inhibition concentration (MIC) was not known for cefazolin
in our lab, tests were conducted to determine the MIC for this S. aureus strain. The MIC
tubes contained 1.75 mL of TSB, 200 µL of appropriate concentration of cefazolin, and
50 µL of bacteria. The following serial dilutions were prepared in PBS and were further
diluted 1:10 after being added to test tubes in duplicate:
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Table 3: Serial dilutions prepared for MIC - cefazolin
µg/mL
160
80

µg/mL after
1:10 dilution
16
8

40

4

20

2

10

1

5

0.5

2.5

0.25

0

0

As discussed in table 2 and 3, the tubes were prepared, capped, vortexed, and then
they were incubated at 37°C overnight with the caps open. The next morning, each tube
was vortexed again with caps closed and the turbidity measured based on absorbance at
530nm using a spectrophotometer (Spectronic Instruments 20 Genesys).
IX.

Statistical Analysis
Statistical analysis was performed using Minitab Statistical Software (version
14.20). For set time data, two-factor analysis of variance (ANOVA) was used to analyze
the factors of type of set time performed and type of antibiotic used. For DTS data, 3
factors were considered: time, antibiotic used, and curing conditions. For the XRD,
elution, and dissolution, data was compared to the controls to determine if the results
were similar quantitatively. When significant differences were detected with the ANOVA
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tests, data were further analyzed with the Tukey’s range test. Statistical significance was
declared at p<0.05 level of significance.
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Chapter V: Results
I.

Set Time Testing
The results of the set time testing of antibiotic-loaded calcium sulfate and controls
using Vicat and Gilmore testers are shown in Figure 4. All set times took place between
the range 7.25 min and 19.00 min. Bone grafts made with cefazolin took the shortest time
to set in all 3 tests, while vancomycin took the longest to set. Gilmore 2 took on average
between 5-8 extra minutes to set after Vicat/Gilmore 1 testing was complete. Vicat and
Gilmore 1 results were very similar, with no more 0.12 minute difference between each
other, but Vicat always had the faster set time in all 4 samples. Results of ANOVA
identified that there were statistically significant differences between set times of calcium
sulfate mixed with different antibiotics or control (p=0.0001) and there were difference in
set time type of test (e.g. Vicat, Gilmore 1, and Gilmore 2) (p=0.0001). ANOVA
indicated that there was a significant interaction between factors of antibiotic added and
type of penetration test performed (p=0.0001).
In general, Tukey’s range tests indicated that set times for each type of antibiotic
added to the MIIG® X3 were greatest in Gilmore 2 tests as compared to Gilmore 1 and
Vicat tests (p<0.001). For both the Vicat and Gilmore 1 tests, addition of cefazolin
reduced set time the most, followed by control, amphotericin B and then vancomycin. In
the Gilmore 2 test, the addition of cefazolin (p=0.0001) to the calcium sulfate still
resulted in the fast set time, but there was no statistical differences between set times of
the other calcium sulfate materials with or without the added amphotericin B or
vancomycin (p=0.3575).
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Set Time of Antibiotic-Loaded Calcium Sulfate
Mixtures & Controls
20.00
18.00
16.00
Set Time (min)

14.00
12.00
10.00

b

a

b

b

a

a

a

Amp B
Cefazolin
Vancomycin
Control
a

a
c

c

a

8.00
6.00
4.00
2.00
0.00
Vicat

Gilmore 1

Gilmore 2

Figure 4: Set time using Vicat & Gilmore testing apparatus of the antibiotic-loaded
calcium sulfate bone grafts; statistical significant differences within test groups are
represented by letters (p<0.05)

II.

Calcium Sulfate Conversion
X-Ray Diffraction (XRD) results are shown in Figure 6. Intensity peaks at
2θ=29.1 & 29.7 were used to calculate percentages of dihydrate and hemihydrate,
respectively. The compositions were all very similar with only 1.75% difference between
the highest and lowest compositions. Results of ANOVA indicated that there were no
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statistically significant differences between dihydrate compositions of the calcium sulfate
mixed with different antibiotics or control (p=0.251).

Dihydrate
Peak

Hemihydrate
Peak at
2θ=29.7

Figure 5: Representative XRD spectra of calcium sulfate showing key peaks44
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Composition of Antibiotic-Loaded and Control
Calcium Sulfate Bolus thru XRD Testing
100.00
Amphotericin B

90.00
80.00

91.16 91.30 90.08 91.82

Cefazolin
Vancomycin

Amount (%)

70.00

Control

60.00
50.00
40.00
30.00

20.00
10.00
8.84

0.00
Dihydrate

8.70

9.92

8.18

Hemihydrate

Figure 6: Percent of hemihydrate & dihydrate present in each antibiotic-loaded & control
calcium sulfate bolus using XRD testing; no statistical differences between groups
(p=0.25)

III.

Chemical Structure
Infrared spectra from FTIR analysis are shown in Figures 7 (amphotericin B), 8
(cefazolin), and 9 (vancomycin). In the figures, each sample has a comparison of the
control and calcium sulfate accelerant below it. For each sample, there is a consistent
peak at around 1100cm-1 wavenumbers, which is associated with the SO4 asymmetric
stretch, and a smaller peak at 3500cm-1 wavenumbers, which is associated with the
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hydrocarbons and other organic substances, to represent calcium sulfate peaks, which
were expected. There are negligible variations between each IR spectrum, and the
spectrums were very similar.

Hydrocarbon and
organic substances
around 3500cm-1

S-O bonds
at 1100cm-1

Figure 7: IR spectrum of amphotericin B-loaded MIIG® X3 sample
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Figure 8: IR spectrum of cefazolin-loaded MIIG® X3 sample

Figure 9: IR spectrum of vancomycin-loaded MIIG® X3 sample
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IV.

Surface Characteristics
Images from the Scanning Electron Microscope (SEM) are shown in Figure 10 (A
through H). The material set for over 72 hours and then fractured into smaller pieces with
a hammer. The surface for each sample was very uneven and had many pores/holes.
Crystalline structures between each sample looked similar, with no observable variations.
From EDS analysis, oxygen had the highest weight% for each sample, followed by
calcium, and then sulfur. The control bolus had the lowest wt% of oxygen at 55.8 ± 1.1%
among the other bolus, but had the highest wt% of sulfur and calcium at 18.8 ± 0.58%.
Amphotericin B and cefazolin-loaded bolus have almost identical wt% for each element.
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Figure 10: SEM Images of internal structure of MIIG® X3 Bolus A. Amphotericin Bloaded bolus (1500x w/EDS) B. Amphotericin B-loaded bolus (2500x) C. Cefazolinloaded bolus (1500x w/EDS) D. Cefazolin-loaded bolus (2500x) E. Vancomycin-loaded
bolus (1500x w/EDS) F. Vancomycin-loaded bolus (2500x) G. Control bolus (1500x
w/EDS) H. Control bolus (2500x)

V.

Mechanical Testing
Results from the DTS testing of MIIG® X3 test and control samples in the wet
and dry conditions are shown in Figure 11. Samples cured in FBS usually had a lower
compressive strength than air cured samples, with the exception of amphotericin B and
control samples. The highest diametral tensile strength was seen at 24hr/Air Cured with
amphotericin B (18.54MPa), while the lowest diametral tensile strength was seen in the
24hr/FBS Cured Control sample (8.40MPa). For 24hr/FBS cured, antibiotics improved
diametral tensile strength above control. Results of ANOVA identified that there were
statistically significant differences between Diametral tensile strength of calcium sulfate
mixed with different antibiotics or control (p=0.0001) and there were difference in type
of test (e.g. 1hr/Air Cured, 1hr/FBS Cured, 24hr/Air Cured, and 24hr/FBS Cured)
(p=0.0001). ANOVA indicated that there was a significant interaction (p=0.0001).
In general, Tukey’s range tests indicated that DTS values for each type of
antibiotic added to the MIIG® X3 were greatest in 24hr/Air Cured tests as compared to
1hr/Air Cured, 1hr/FBS Cured, and 24hr/FBS Cured (p=0.0001). Amphotericin B was
significantly different than the other 2 antibiotics and control (p=0.0021). Cefazolin vancomycin (p=0.9546) and vancomycin - control (p=0.0632) were significantly similar,
but cefazolin and control (p=0.0165) were different.
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Diametral Tensile Strength for each AntibioticLoaded Calcium Sulfate Bolus & Control
a
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Figure 11: Diametral tensile strength of antibiotic-loaded calcium sulfate bolus;
statistical significant differences within each test group are represented by letters (p<0.05)

VI.

Elution Testing
The results of the HPLC determination of antibiotics in eluates from vancomycin
and cefazolin-loaded calcium sulfate samples obtained from a 28 day study are shown in
Figures 12 (daily release) and 13 (cumulative release). Antibiotic release was the highest
on day 1 for both vancomycin and cefazolin at 1113.7 ± 38.8μg/mL and 2359.0 ±
106.3μg/mL, respectively; but cefazolin had more than twice the amount of antibiotic
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released compared to vancomycin. After Day 1, cefazolin had a slightly higher release
than vancomycin, except at Days 21 & 28. At Day 7, release was almost identical for
both vancomycin and cefazolin at 518.9 ± 29.2μg/mL and 518.5 ± 49.1μg/mL,
respectively, which were also both antibiotics’ lowest eluent concentrations. After 28
days, 5680.4 ± 147.4μg/mL was released for vancomycin and 7074.8 ± 309.4μg/mL for
cefazolin. Considering that 350mg of both antibiotics were added to a 5cc bolus, this
gives us 70mg/mL of antibiotic added to the bolus. The amount of antibiotic released
from each bolus was only 8.1% and 10.1% overall for vancomycin and cefazolin,
respectively. When compared to the overall cumulative release, 19.6% of vancomycin
was released on day 1 and 33.3% for cefazolin. Results of ANOVA showed that there
were statistically significant differences between daily release concentrations of calcium
sulfate mixed with different antibiotics or control (p<0.05). Tukey’s range test revealed
that Day 1 was significantly different than all the other days (p<0.05). Days 3 & 7
(p=0.0059) and Days 7 & 14 (p=0.0029) were also significantly different.
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Figure 12: Elution behavior of sterile vancomycin and cefazolin-loaded calcium sulfate
bolus in PBS at 37°C in a 28 day study. Daily release concentrations are shown.
Statistically significant differences are represented by letters (p<0.05)
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Figure 13: Elution behavior of sterile vancomycin and cefazolin-loaded calcium sulfate
bolus in PBS at 37°C in a 28 day study. Cumulative release concentrations are shown.

VII.

Dissolution Testing
The results of the percent change in mass of the pellets during the elution tests are
shown in Figure 14. The results were very similar, with only a 0.05g difference between
highest and lowest dissolution averages. ANOVA identified that there were no
statistically significant differences between percent mass change of calcium sulfate mixed
with different antibiotics or control (p=0.782).
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27

Dissolution of Antibiotic-Loaded and Control
Calcium Sulfate Bolus during Elution Testing
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Amphotericin B

Cefazolin

Vancomycin
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2.00

1.00

0.00

Total Dissolution
Figure 14: Amount of dissolution during a 28 day elution testing for each antibioticloaded & control calcium sulfate bolus; no statistical differences between groups (p=0.78)

VIII.

Turbidity study
The results for the determination of the MIC of cefazolin against the S. aureus in
turbidity tests are shown in Fig 15. The minimum inhibition concentration (MIC) for
cefazolin against S. aureus was less than 0.25μg/mL. Concentrations below 0.25μg/mL
were not tested, so the exact MIC was not determined. The activity of the antibiotics in
the test eluents to inhibit bacterial growth is shown in Figures 16 and 17 for vancomycin
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and cefazolin eluents, respectively. Eluents collected over the 28 day test period from
both vancomycin and cefazolin-loaded calcium sulfate completely inhibited growth of
bacterial as compared to positive controls and control eluents without antibiotic.

Minimum Inhibition Concentration of
Cefazolin against S. aureus Cowan I
1.00
0.90

Absorbance @ 530nm

0.80
0.70
0.60
0.50
0.40
0.30
0.20
0.10
0.00
MIC 16

MIC 8

MIC 4

MIC 2

MIC 1

MIC 0.5 MIC 0.25

Figure 15: Absorbance readings from minimum inhibition concentration (MIC)
conducted on cefazolin against S. aureus Cowan I
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Turbidity Study Conducted on Vancomycin-Loaded
Bolus
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Figure 16: Absorbance readings from turbidity study conducted on vancomycin-loaded
calcium sulfate bolus against S. aureus Cowan I
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Turbidity Study Conducted on CefazolinLoaded Bolus
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Figure 17: Absorbance readings from turbidity study conducted on cefazolin-loaded
calcium sulfate bolus against S. aureus Cowan I
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Chapter VI: Discussion
We investigated if MIIG® X3 may be used in local drug delivery with three
different classes of antibiotics: amphotericin B (polyene antifungal), cefazolin (β-lactam
antibacterial), and vancomycin (glycopeptide antibacterial). These antibiotics were
chosen for their effectiveness against microbials that commonly cause osteomyelitis,
especially S. aureus as well as S. epidermis and C. albicans. A major goal was to
determine if the antibiotics would have any effect on the chemical reaction that converts
hemihydrate to dihydrate, because a key aspect of loading antibiotic into calcium sulfate
bone graft is to not hinder its mechanical strength. We tested physical properties with set
time, calcium sulfate conversion with x-ray diffraction, chemical structure with Fourier
transform infrared spectroscopy, surface characteristics with scanning election
microscope, and mechanical strength with Diametral tensile strength test. We also sought
to determine the elution of the antibiotics from the calcium sulfate bolus in phosphate
buffered saline (PBS). Dissolution of the calcium sulfate bolus was analyzed to determine
if antibiotic release was sufficient to inhibit bacterial growth.
We found that the antibiotics cefazolin and vancomycin were easily incorporated
into the MIIG® X3 kit by dissolving into the supplied water and then combining with
calcium sulfate to form the bone graft. Amphotericin B did not dissolve completely in the
supplied water for mixing the bone graft, because of its lower solubility; however, it was
still able to be mixed. None of the evaluated antibiotics in this study prevented setting of
the bone graft based on penetration tests or the conversion of hemihydrate to dihydrate as
determined by XRD. There were some differences in set time and DTS values based on
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the type of antibiotic added to the MIIG® X3 cement, but it did not have an effect on the
hemihydrate – dihydrate reaction or the dissolution rates. Statistical analyses
demonstrated that cefazolin appeared to be the only antibiotic to be significantly different
from the others on set time. Cefazolin caused the calcium sulfate to set approximately 31%
faster compared to the control based from Gilmore 2 results, but not so quick that a
physician could not use it for local drug delivery. Of course, a physician would need to be
aware of this happening. Statistical analyses also showed that the addition of
amphotericin B had a significant effect on the DTS of the bone grafts as compared to the
other antibiotic and antibiotic free bone grafts. Addition of antibiotics to bolus appeared
to have a slight improvement in DTS values over control samples in 1 hour/Air cured and
24 hours/FBS cured conditions. FBS cured conditions, while still an in vitro test, are
more representative of clinical applications when calcium sulfate is implanted into the
body. These results suggest that addition of these three antibiotics have no real negative
effects on the physical-chemical properties of the MIIG® X3 calcium sulfate bone graft.
A study conducted by Bohner et al. shows that antibiotics may affect a bone
graft’s tensile strength and setting time. 66 Calcium phosphate pellets loaded with
gentamicin, affected physical-chemical properties of the bone graft. Setting time
increased from 2 to 4.5 minutes with 3% (w/w) gentamicin, but then slowly decreased to
3.75 minutes as the amount of gentamicin was increased to 16% (w/w). Tensile strength
increased from 0.4 to 1.6 MPa as the amount of gentamicin was increased to 16% (w/w).
The Bohner study attributed these changes to the sulfate ions present in gentamicin,
which induces a finer microstructure in the material. Even though this study used calcium
phosphate, the physical-chemical properties of calcium phosphate and calcium sulfate are
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similar. We may conclude by comparing previous studies and our study that adding
antibiotic may have an effect on setting time and tensile strength, but conversion of
hemihydrate to dehydrate is unaffected.
Results from XRD and FTIR testing in our investigation showed that antibiotics
did not have an overall effect on the chemical reaction of hemihydrate to dihydrate. FTIR
charts for control and antibiotic-loaded MIIG® X3 appear very similar with little
differences seen in the peaks. XRD results demonstrated that the compositions of
dihydrate in antibiotic-loaded MIIG® X3 were almost identical to the controls. The
dihydrate composition levels were between 90.1%-91.8%. A study by Doadrio et al. had
similar results to our study.25 They conducted XRD and FTIR tests on their cephalexinloaded calcium sulfate pellets and concluded that the presence of cephalexin into the
bone graft does not alter neither the physical-chemical behavior of the bone grafts nor
produce structural changes on the pellets. Cephalexin is a cephalosporin antibiotic that is
in the same class of antibiotic as cefazolin with very similar structures and mechanisms
of action, therefore the Doadrio results are relevant to our study. A study by Jackson et al.
demonstrated that vancomycin loaded into rapidly resorbing calcium sulfate pellets had a
delayed release compared to the other two antibiotics, amikacin and gentamicin.48 They
did not observe any significant differences in composition rates among the samples tested.
Peaks at 2θ = 25° and 30° observed during XRD testing were tiny and indicated that very
little hemihydrate was present. Results from our XRD study were similar to studies by
Jackson et al. and Doadrio et al. of antibiotic-loaded calcium sulfate pellets and suggests,
at least for the antibiotics evaluated, there is little effect of the antibiotics on the
conversion of hemihydrates to dihydrate. EDS analysis from SEM showed us that oxygen
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amounts increased with the addition of antibiotics compared to the control. The increase
was very small, within 6%, and may be associated with the additional oxygen atoms that
the antibiotics introduce into the mixture.
Cefazolin and vancomycin had elution characteristics similar to previous studies
where there was a typical burst release in day 1, but lower concentrations in later
days.22,30,48 Cefazolin-loaded specimens released almost twice as much antibiotic as the
vancomycin-loaded specimens did initially and remained greater throughout the study.
Daily release levels of vancomycin were more similar to cefazolin after day 14. Jackson
et al. described calcium sulfate antibiotic elution from a pellet that dissolved within 24
hours.48 Amikacin and gentamicin pellets fully dissolved within 12 hours, while
vancomycin pellets released antibiotic all the way to 24 hours. Vancomycin had a spike
in release at 1 hour and then another burst at 4 and 8 hours and then slowly decreased
until it dissolved. They attributed this to vancomycin’s larger nine ring structure, as seen
in Figure 18. This is further supported by data in this study; cefazolin’s smaller structure
may have allowed it to elute more quickly than vancomycin.
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Figure 18: Comparison of cefazolin (left) and vancomycin (right) molecular structure;
vancomycin’s larger structure slowed release from bolus

Recovery rates of the antibiotics cefazolin and vancomycin were approximately
10.1% and 8.1%, respectively. Heijink et al., reported 39% recovery of their vancomycin
from OSTEOSET®, a calcium sulfate product also offered by Wright Medical.24 The
higher percentages compared to our percentages may be contributed to the smaller pellets
(~0.1cc/pellet) used in the OSTEOSET® kit; there is a higher surface area exposed to the
PBS. In their study, they also mixed vancomycin with DBX, an allograft bone void filler
made by Synthes (West Chester, PA), and Collagraft, a synthetic bone graft comprised of
bovine collagen and hydroxyapatite/tricalcium phosphate (HA/TCP) granules made by
Zimmer (Warsaw, IN). They were only able to retrieve 9% and 23%, respectively, of the
vancomycin, which further supports that calcium sulfate is better suited for local drug
delivery. Another study done by Udomkusonsri et al. showed that cefazolin-loaded
calcium sulfate pellets had a recovery rate of 93.84% after a 15 day elution study in
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PBS.27 They only had a 24.10% recovery rate for cefazolin-loaded PMMA pellets. They
believed calcium sulfate had a higher porosity which contributed to the higher antibiotic
release. Their conclusion was that calcium sulfate may release antibiotic at a much higher
concentration and be better in local drug delivery compared to PMMA.
By examining the statistical analysis, we may conclude that the dissolution rates
were similar among the 4 test groups: control, amphotericin B, cefazolin, and
vancomycin. Dissolution results were not indicative of previous studies conducted with
antibiotic-loaded calcium sulfate pellets. In a study conducted by Richelsoph et al.,
daptomycin and tobramycin were mixed with calcium sulfate and dissolution and elution
rates were measured in saline.67 They discovered that the daptomycin-loaded pellets
dissolved more rapidly than tobramycin-loaded pellets. Dissolution of the calcium sulfate
material appeared to be dependent on the antibiotic. In our case, there was no difference
in dissolution with the 3 antibiotics, which was different than Richelsoph et al. A
comparison between our dissolution results and Richelsoph’s results would be biased.
Richelsoph used much smaller pellets, while our study used a bolus; surface areas would
be very different. Overall, we may conclude that dissolution rates are dependent on the
chemical properties of the antibiotic used, such is the case with the study conducted by
Bohner et al. and the extra sulfate ions produced from the gentamicin added.66
Cytotoxicity to osteoblasts is a concern with the higher concentrations of
antibiotic. A study conducted by Edin et al. tested the effects of cefazolin and
vancomycin on osteoblast-like cells.23 They used MG-63 human osteosarcoma cell line
and exposed it to different concentrations of the antibiotics ranging between 010,000µg/mL and then 100-1000µg/mL to define cefazolin’s toxic level. They
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determined that levels of 1000µg/mL or less for vancomycin and 100µg/mL or less for
cefazolin have little or no effect on the cells. But concentrations of 10,000µg/mL for
vancomycin and cefazolin caused cell death. Levels of 200µg/mL for cefazolin did cause
significant decrease in cell replication. They concluded that vancomycin is less toxic than
cefazolin at higher concentrations and may be a better antibiotic for local drug delivery.
The highest concentrations for vancomycin were seen on Day 1 (1113.7 ± 38.8µg/mL),
which were significantly below the 10,000µg/mL level. Highest concentrations for
cefazolin were also seen on Day 1 (2359.0 ± 106.3µg/mL) and were below 10,000µg/mL
level, but higher than the 200µg/mL level that may cause significant decreases in
osteoblastic cell replication. After day 1, cefazolin concentrations were less than the
200µg/mL and may not affect cell proliferation. This would certainly have to be
considered by a physician planning on administering cefazolin though local drug delivery.
From our results in the turbidity study conducted, S. aureus was inhibited from growing
even at the lowest concentrations 518.5 ± 49.1µg/mL at Day 7. The MIC for cefazolin
was determined to be lower than 0.25µg/mL, therefore a lower concentration of cefazolin
may be considered in future studies. In a separate study conducted by Sealy et al., they
loaded amphotericin B into hydroxyapatite, PMMA, and beta-tricalcium phosphate
beads.68 The released concentrations were between 1.75 and 2.0µg/mL over 110 days for
all the beads. In the Sealy study, amphotericin B-loaded pellets were determined to be not
toxic to osteoblasts during 72 hours of exposure in tissue culture medium.
The insolubility of amphotericin B prevented us from determining concentration
and release rates with the high performance liquid chromatography (HPLC).
Amphotericin B would only dissolve completely in a solvent such as methanol or
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dimethyl sulfoxide. These solvents were added to test eluents before running the HPLC,
but we were still unsuccessful in measuring the amount of amphotericin B. A concern we
have is that the amphotericin B’s antibiotic level was relatively low in the calcium sulfate
bolus formulation, because of its toxicity within the body and as such concentrations in
eluents may also be low. Serial concentrations for standard curves went as low as
5µg/mL, and were detected by HPLC, but HPLC still did not detect any antibiotic within
eluents. If all the antibiotic was released in day 1, concentration levels would be almost
3,400µg/mL and would have been high enough to detect. Replacing PBS with one of the
solvents was considered, but deemed impractical and unrealistic in a clinical aspect. An
alternate spectrophotometric detection method for amphotericin B was tried to measure
concentrations in the eluents, but also was unsuccessful. A third biologically based
method based on zone of inhibition may provide a means to estimate released
amphotericin B’s concentrations, if any antibiotics were even released. The test would
use C. albicans as the microorganism since amphotericin B is used to treat fungal
infections. The fungus will be grown on an agar plate over 48 hours. Paper disks
saturated with the eluent would be placed on the plate and if the antibiotic is still
functional, it will create an inhibited zone around the disk. By measuring this zone of
inhibition and comparing it to zones around known concentrations of amphotericin B on
saturated disks, concentration of amphotericin B in the eluent may be estimated. These
experiments are planned to be conducted with Dr. Courtney at the VA Hospital, Memphis,
TN, in the near future.
In the turbidity study conducted on cefazolin and vancomycin eluents with S.
aureus, the antibiotic concentrations were able to inhibit growth of the bacteria over the
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entire 28 day period of the study. In these studies, we may only conclude that the bacteria
were inhibited from growing, but not eliminated. From our results, we may state that
bacteria growth was inhibited by almost ~98% compared to positive controls.
Udomkusonsri et al. also tested the cefazolin eluents effectiveness against Bacillus
subtilis, another Gram-positive bacteria.27 Eluents inhibited the bacteria’s growth
successfully and they determined that mixing cefazolin with calcium sulfate would not
affect cefazolin’s antibacterial activity. Comparisons can still be made between our study
and referenced studies, since the amount of pellets packed into a bone void is almost
equivalent to a 5cc bolus. However, there are not many studies available using a larger
bolus as our study used. At the end of the 28 day elution study, a great amount of bolus
and antibiotic remained. Inhibition of bacterial growth was seen all the way to the end,
which leads us to believe that the bolus may be used for extended amounts of protection,
perhaps up to 3-4 months. Of course biofilm formation is a concern, but if antibiotic level
is high enough, then it may combat the biofilm development.
In vivo studies have been conducted with antibiotic-loaded calcium sulfate
pellets.26,29,38,40,48 A study conducted by Xie et al. compared vancomycin-loaded calcium
sulfate to vancomycin-loaded borate glass.26 They infected 65 rabbits with methicillinresistant S. aureus (MRSA) and split them into 4 groups. Each rabbit received treatment
by debridement and the void was filled with: nothing (group 1), pure borate glass (group
2), vancomycin-loaded calcium sulfate (group 3), and vancomycin-loaded borate glass
(group 4). The vancomycin-loaded calcium sulfate and borate glass had the best results
against the MRSA with 73.33% and 81.25% kill rates, respectively. It was observed that
the calcium sulfate had fully resorbed and had better bone growth compared to the borate
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glass only being partially reabsorbed. Even though antibiotic levels were different from
our study, it is still important to verify that calcium sulfate may be used as a local drug
delivery system successfully. Richelsoph et al. conducted an in vivo study involving adult
Spanish-Boer goats implanted with amikacin-loaded calcium sulfate and PMMA beads. 48
The amikacin-loaded calcium sulfate beads sufficiently reduced bacterial growth than
amikacin-loaded PMMA beads. Levels of antibiotics released in these studies were above
the MIC of the infecting microbial, which was similar to our study with antibiotic release
being higher than MIC of S. aureus. From these referenced studies we may conclude that
antibiotic-loaded injectable calcium sulfate is a potentially effective clinical treatment for
osteomyelitis.
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Chapter VII: Conclusions
Aims of this study were to characterize effects of mixing one of the three
antibiotics, amphotericin B, cefazolin, and vancomycin, on physical, chemical, and
mechanical properties of MIIG® X3. The properties evaluated were set time, phases,
chemistry, and morphology via Vicat and Gilmore penetration tests, X-Ray Diffraction
(XRD), Fourier Transform Infrared Spectroscopy (FTIR), and Scanning Election
Microscope (SEM), respectively. Diametral Tensile Strength (DTS) was also performed
to provide information on mechanical strength. The in vitro release of the antibiotics
from clinically relevant bolus samples of injectable material over 28 days in saline
solution using High Performance Liquid Chromatography (HPLC) techniques was
measured. The dissolution of the bolus by evaluated for mass change during the 28 day
elution study was also determined. Finally, the ability of the released antibiotics to inhibit
the in vitro growth of representative microbes associated with osteomyelitis was
evaluated. Based on the result of this work we conclude that:


Mixing of amphotericin B, cefazolin, and vancomycin with MIIG® X3 calcium
sulfate did not adversely affect set times, chemical or physical structure,
mechanical properties, or degradation times as compared to antibiotic free
formulation. Bolus will still set as normal MIIG® X3 and will still remain strong
enough to be used in non-load bearing fracture fixation or as bone void filler.



MIIG® X3 loaded with cefazolin and vancomycin was able to release the
antibiotics at levels that inhibited in vitro growth of S. aureus, a model pathogen,
for up to 28 days.
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These results suggest that calcium sulfate cements may be used to locally delivery
vancomycin and cefazolin antibiotics to treat/prevent osteomyelitis.



Release of amphotericin B from calcium sulfate could not be determined in this
study because of solubility issues.
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Chapter VIII: Future Work
This preliminary investigation provided basic information on the effects of the
antibiotics, amphotericin B, cefazolin, and vancomycin, on the physical and chemical
characteristics of injectable calcium sulfate bone graft and on levels and antibacterial
properties of released vancomycin and cefazolin in vitro. Future research is needed to
address additional important questions. Since release levels of amphotericin B were not
determined, a biological based semi-quantitative zone of inhibition assay using C.
albicans may be useful to estimate the release amount and activity of amphotericin B.
Alternatively, other more soluble forms of amphotericin B may utilized that would
provide amounts of the released antibiotic that could be detected and that would have
antimicrobial properties.
Another interesting possibility would be to load MIIG® X3 with growth factors,
anti-inflammatory and anti-cancer drugs, or painkillers and to evaluate effects on cement
and ability of cement to delivery agents locally. There have been previous studies already
conducted incorporating these drugs, and it was discovered that they had no physicalchemical effect on the calcium sulfate. 20,21 Mixing different types of antibiotics is also a
possibility and may be tested by using the series of analysis that our study utilized.
Mixing one antibiotic effective against Gram-negative bacteria and another one effective
against Gram-positive bacteria would help combat multiple microorganisms at once,
since osteomyelitic infections may be caused by two or more bacteria. Increasing dosages
for each antibiotic is a possibility for clinical studies, but it would require a cytotoxicity
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study to be performed before implantation. Cytotoxicity studies were not performed in
our study and would further answer any questions that may remain.
One of the most important inquiries is the materials effectiveness in in vivo tests.
It would be interesting to observe how this material performs in animal studies or even
clinical studies. Another concern would be how long would it take for the bolus to
completely dissolve and if it would consistently release high concentrations of antibiotic
all the way till the end. If the bolus is able to release antibiotics at a high enough
concentration that keeps it above the microorganism’s MIC, then it may remain effective.
But if the bolus takes some time to dissolve and antibiotic release is low, then biofilm
formation could become a problem. Biofilm formation tests would be beneficial in this
study to discover if biofilm is a concern when using a large bolus. If biofilm forms on the
surface of the bolus, then it would need to be removed, since eradication of biofilm is
nearly impossible and use of a bolus would then become ineffective and useless.
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Chapter X: Appendix
I.

Results

Table 4: Set time of antibiotic-loaded calcium sulfate bolus
Amphotericin B
Vicat
Gilmore 1
Gilmore 2

10.58 ± 0.43
10.66 ± 0.43
17.40 ± 1.16

Cefazolin
Vancomycin
Mean ± Std. Dev (min.)
8.10 ± 0.84
11.81 ± 0.69
8.17 ± 0.83
11.90 ± 0.71
12.00 ± 0.92
18.43 ± 0.56

Control
9.48± 0.26
9.60 ± 0.32
17.73 ± 0.56

Table 5: Composition of antibiotic-loaded and control calcium sulfate bolus thru XRD
testing
Amphotericin B
Intensity at 2θ=29.1
Intensity at 2θ=29.7
Dihydrate (%)
Hemihydrate (%)

1796 ± 307
169 ± 28
91.2 ± 2.5
8.8 ± 2.5

Cefazolin
Vancomycin
Mean ± Std. Dev.
1704 ± 647
1625± 265
154 ± 46
177 ± 27
91.3 ± 1.9
90.1 ± 1.3
8.7 ± 1.9
9.9 ± 1.3

Control
1335 ± 342
116 ± 22
91.8 ± 1.2
8.2 ± 1.2

Table 6: Diametral tensile strength at fracture for each drug in either Fetal Bovine Serum
(FBS) or air
Amphotericin B
1 Hour & Air Dried
1 Hour & FBS Dried
24 Hour & Air Dried
24 Hour & FBS
Dried

10.31 ± 0.21
10.71 ± 0.44
18.54 ± 1.07
10.87 ± 0.68

Cefazolin
Vancomycin
Mean ± Std. Dev (MPa)
9.43 ± 0.67
9.40 ± 0.16
9.19 ± 0.47
8.91 ± 0.48
10.90 ± 0.77
11.90 ± 0.54
8.97 ± 0.59
9.19 ± 0.42
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Control
9.10 ± 0.61
10.27 ± 0.96
16.08 ± 1.18
8.40 ± 0.49

Table 7: Elution behavior of sterile vancomycin and cefazolin-loaded calcium sulfate
bolus in a 28 day study
Day

1
3
5
7
14
21
28

1
3
5
7
14
21
28

Vancomycin
Cefazolin
Daily Release Concentration (μg/mL)
Mean ± Std. Dev. Coefficient Mean ± Std. Dev.
Coefficient of
of
Variation (%)
Variation
(%)
1113.70 ± 38.81
3.49
2358.96 ± 106.29
4.51
822.62 ± 23.22
2.82
1019.84 ± 102.26
10.03
624.15 ± 18.56
2.97
685.98 ± 67.19
9.79
518.89 ± 29.20
5.63
518.53 ± 49.10
9.47
834.94 ± 10.29
1.23
1055.89 ± 98.49
9.33
891.36 ± 29.53
3.31
795.99 ± 60.52
7.60
718.77 ± 33.63
4.68
639.56 ± 37.85
5.92
Cumulative Release Concentration (μg/mL)
Mean ± Std. Dev. Coefficient Mean ± Std. Dev.
Coefficient of
of
Variation (%)
Variation
(%)
1113.70 ± 38.81
3.49
2358.96 ± 106.29
4.51
1936.32 ± 61.62
3.18
3378.80 ± 161.44
4.78
2560.47 ± 73.71
2.88
4064.78 ± 203.49
5.01
3079.36 ± 94.55
3.07
4583.31 ± 243.73
5.32
3914.30 ± 100.82
2.58
5639.20 ± 316.54
5.61
4805.67 ± 120.68
2.51
6435.19 ± 362.07
5.63
5680.36 ± 147.36
2.67
7074.75 ± 390.40
5.52

Table 8: Dissolution of antibiotic-loaded and control calcium sulfate pellets during a 28
day elution test
Amphotericin B
Initial Weight (g)
Final Weight (g)
Total Dissolution (g)
Total Dissolution (%)

10.22 ± 0.16
9.75 ± 0.13
0.47 ± 0.07
4.58 ± 0.69

Cefazolin
Vancomycin
Mean ± Std. Dev.
10.30 ± 0.22
10.23 ± 0.16
9.85 ± 0.21
9.75 ± 0.20
0.44 ± 0.11
0.48 ± 0.07
4.29 ± 1.00
4.73 ± 0.70
80

Control
10.30 ± 0.12
9.81 ± 0.12
0.49 ± 0.07
4.77 ± 0.63

Table 9: Turbidity study of cefazolin and vancomycin-loaded calcium sulfate bolus
against Staphylococcus aureus Cowan I

Blank
Negative Control
Positive Control
Control - Day 1
Control - Day 3
Control - Day 5
Control - Day 7
Control - Day 14
Control - Day 21
Control - Day 28
Day 1
Day 3
Day 5
Day 7
Day 14
Day 21
Day 28
MIC - 16 μg/mL
MIC - 8 μg/mL
MIC - 4 μg/mL
MIC - 2 μg/mL
MIC - 1 μg/mL
MIC - 0.5 μg/mL
MIC - 0.25 μg/mL
MIC - 0 μg/mL

Vancomycin
Cefazolin
Absorbance @ 530nm
Mean ± Std. Dev.
0.012 ± 0.003
0.000 ± 0.002
0.004 ± 0.005
0.022 ± 0.001
0.964 ± 0.021
0.967 ± 0.027
0.965 ± 0.029
0.957 ± 0.023
0.939 ± 0.018
0.958 ± 0.023
0.958 ± 0.037
0.932 ± 0.021
0.965 ± 0.049
0.019 ± 0.002
0.022 ± 0.001
0.020 ± 0.002
0.021 ± 0.002
0.021 ± 0.004
0.020 ± 0.001
0.021 ± 0.004
0.021 ± 0.001
0.022 ± 0.002
0.018 ± 0.006
0.023 ± 0.002
0.020 ± 0.001
0.020 ± 0.003
0.021 ± 0.001
0.011 ± 0.013
0.011 ± 0.013
0.012 ± 0.007
0.012 ± 0.002
-0.001 ± 0.001
-0.003 ± 0.001
-0.002 ± 0.000
0.924 ± 0.028
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